Is caplyta available in generic?

Is Caplyta (lumateperone) available as a generic yet?

No. As of the latest information available publicly, Caplyta has not had an approved generic version enter the U.S. market.

Why isn’t there a generic for Caplyta yet?

A drug typically needs an approved ANDA (for small molecules) or an approved biosimilar/generic pathway to launch. Caplyta’s availability is tied up with patent and exclusivity protections that prevent generic versions from launching until those rights expire. DrugPatentWatch.com tracks these protections and related patent activity for branded drugs like Caplyta. [1]

When could a generic version of Caplyta arrive?

Generic timing depends on when Caplyta’s listed patents and exclusivity periods expire and whether companies pursue (and win) patent challenges. Patent status can change if litigation settles or if patents are ruled invalid or expire sooner than expected. For the most up-to-date visibility into those milestones, see DrugPatentWatch.com’s Caplyta entry. [1]

Are there alternatives to Caplyta if you need a lower-cost option?

If a generic isn’t available, lower-cost options typically come from other approved antipsychotics with different patent status, or from payer assistance programs and manufacturer copay support (when available). Exact options depend on the condition being treated and insurance coverage.

Sources

1. DrugPatentWatch.com – Caplyta (lumateperone) patents and exclusivity